Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300793 · ClinicalTrials.gov registry record · Phase 1
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01300793: Clinical Trial Phase 1 study, sponsored by University of California, San Francisco.
NCT01300793 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01300793, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Primary objective of the study is to determine the maximum tolerated dose (MTD) of bortezomib (Velcade) in combination with rituximab, ifosfamide, carboplatin and etoposide for adult patients with relapsed or refractory aggressive B-cell lymphoma. The secondary objectives are to assess the tolerability and safety, the response rate, rate of autologous stem cell transplant and CD34+ progenitor cell collection and engraftment after treatment with this regimen.
Interventions
- DRUG Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Why NCT01300793 stopped before completion
NCT01300793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide is the first listed.
NCT01300793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01300793 about?
NCT01300793 is a clinical study titled "Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide". Primary objective of the study is to determine the maximum tolerated dose (MTD) of bortezomib (Velcade) in combination with rituximab, ifosfamide, carboplatin and etoposide for adult patients with relapsed or refractory aggressive B-cell lymphoma. The secondary objectives are to assess the tolerabil...
What is the current status of trial NCT01300793?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01300793?
The interventions under investigation include: Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide (DRUG).
Who is sponsoring clinical trial NCT01300793?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01300793's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia